Table 3.
Summary of tumor-targeted, MRI-traceable nanotheranostics for cancer gene therapy
| Imaging probe | Targeting strategy | In vivo tumor model | Gene | Purpose of investigation | Important outcome(s) | Ref |
|---|---|---|---|---|---|---|
| SPIONs (T2 MRI) |
EPPT1 peptide targeting uMUC1 and MPAPs | Pancreatic cancer (6606PDA) | siPLK1 | Evaluate the potential of an siRNA integrated theranostic system targeting PLK1 to treat pancreatic ductal adenocarcinoma | Significant accumulation of siPLK1-StAv-SPIONs in the tumor site; efficient PLK1 silencing that significantly inhibited tumor growth | 88 |
| SPIONs (T2 MRI) |
MT | Liver cancer (HepG2) | HSV-TK/GCV | Develop an MRI-guided, MT agent for hyperthermia-enhanced suicide gene therapy of HCC | T2-weighted MRI images demonstrated enhanced gene delivery and magnetic hyperthermia performance of rod-like M-MSNs compared to sphere-like M-MSNs for suicide gene therapy | 90 |
| SPIONs (T2 MRI) |
HA targeting CD44 | Lung cancer (NSCLC-H1975) | Virotherapy (magnetized AAV2) | Develop a hypoxia-responsive nanotheranostic agent for tumor virotherapy | Specific delivery of AAV2 to the tumor confirmed with MRI; significantly enhanced tumor inhibition through light-triggered virotherapy | 93 |
Abbreviations: AAV2: adeno-associated virus serotype 2; HA: hyaluronic acid; HCC: hepatocellular carcinoma; HSV-TK/GCV: herpes simplex virus thymidine kinase/ganciclovir; M-MSNs: magnetic mesoporous silica nanoparticles; MPAPs: myristoylated polyarginine peptides; MT: magnetic targeting; NSCLCN: non-small- cell lung cancer; PLK1: polo-like kinases; StAv: streptavidin.